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Abstract: 
In recent years the potential for anabolic steroid abuse in equine sports has increased due to the growing 
availability of “designer steroids”. These compounds are readily accessible online in “dietary” or 
“nutritional” supplements and contain steroidal compounds which have never been tested or approved as 
veterinary agents. They typically have unusual structures or substitution and as a result may pass 
undetected through current anti-doping screening protocols, making them a significant concern for the 
integrity of the industry. Despite considerable focus in human sports, until recently there has been limited 
investigation into these compounds in equine systems. In order to effectively respond to the threat of 
designer steroids, a detailed understanding of their metabolism is needed to identify markers and 
metabolites arising from their misuse. A summary of the literature detailing the metabolism of these 
compounds in equine systems is presented with an aim to identify metabolites suitable for incorporation 
into screening protocols by anti-doping laboratories. The future of equine anti-doping research is likely to 
be guided by the incorporation of alternate testing matrices into routine screening, the improvement of in 
vitro technologies that can mimic in vivo equine metabolism, and the improvement of instrumentation or 
analytical methods that allow for the development of untargeted screening, and metabolomics approaches 
for use in anti-doping screening protocols. 
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History of doping in sport 
Among the earliest known examples of doping in sport come from the ancient Greek and Roman cultures 
which are known to have held sporting competition in high regard. Competitors devoted themselves to 
winning at any cost and were said to have consumed numerous substances as a part of the strict diet and 
exercise regimes that accompanied preparation for these competitions. Alcohol, hallucinogenic 
mushrooms, leaves and syrups derived from opium-containing plants, bull urine, and raw animal testicles 
were favourites of these competitors 1,2. Animal sports were also quite common during this time and 
although records relating to the doping of animal competitors during this period are scarce, it is unlikely 
that they would not have been subject to the same types of treatment as their human-counterparts 3,4. 
Among the first known instances of doping in equine sports comes from the fifteenth century where a 
mixture containing anise seed, honey and red arsenic sulphide (sandarac) was reportedly given to horses as 
a stimulant 3, and later from an English regulation reported in 1666 banning the use of “exciting 
substances” in competitive races 3,5. The first well-documented cases of doping in equine sports however 
came to light during the nineteenth century and in response such substances were soon outlawed 3,6. These 
bans were ineffective without a means to police them however, so this lead to the rapid development of 
saliva-based tests to detect alkaloids such as cocaine and heroin 4–7.  
 
Reports of anabolic steroid misuse in equine sports date back to 1941, where an eighteen-year-old 
standardbred US trotter named Holloway was treated with testosterone (17β-hydroxyandrost-4-en-3-one) 
for several months during training, and as a result reportedly regained much of his former racing ability 8. 
More recently, the trainer of the US champion thoroughbred Big Brown admitted to injecting his horses 
with the synthetic anabolic steroid stanozolol ([1',2’]-1’H-pyrazolo[4’,5’:2,3]-17α-methyl-5α-androstan-17β-
ol) during the 2008 Kentucky Derby, although stanozolol was legal in US racing at the time 8. Big Brown won 
the first two races of the series under the effects of stanozolol; however, the horse failed to perform as 
expected in the third race where he was run steroid-free. To combat the growing problem of doping in 
equine sports, the Horseracing Authorities of the United States of America, France, Great Britain and 
Ireland jointly decided in 1961 to coordinate their resources to better manage the future of the industry, as 
equine sports have traditionally been governed by the local authorities in each jurisdiction 9. In 1993 the 
International Federation of Horseracing Authorities (IFHA) was formed and included over 60 members. 
They meet annually to update the International Agreement on Breeding, Racing and Wagering, first 
endorsed in 1974, which outlines the recommended best practice for all jurisdictions, including protocols 
for how to effectively address the problem of doping in equine sports 10. 
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Anabolic androgenic steroids 
Steroids are a class of chemical compounds characterised by their tetracyclic fused ring system consisting of 
three cyclohexane rings (Rings A, B and C) and a cyclopentane ring (Ring D), conferring chemical stability 
and conformational rigidity to the molecule. Furthermore, the rings can be modified at many possible 
positions, and also occur as a variety of stereochemistries and degrees of unsaturation, and they occur 
widely in nature as lipids, hormones and other natural products 11. The structure of anabolic steroids is 
typified in the example of 17α-methyltestosterone (17β-hydroxy-17α-methylandrost-4-en-3-one) as shown 
in Figure 1. 
Figure 1 
 
Steroid compounds can be categorised into number of subclasses, typically based on the number of carbon 
atoms present in their core structure. The most interesting classes in the anti-doping context include; 
cholestanes (C27), which are typified by cholesterol, that are the steroid precursors from which most 
others are ultimately derived; cholanes (C24), which primarily consist of the steroid bile acids; pregnanes 
(C21), which consist of the progestogens and the corticosteroids; androstanes (C19), which form the basic 
framework of most androgens; and estranes (C18), which form the basic framework of some androgens, 
and the estrogens 11,12. Representative examples of each steroid class are shown in Figure 2. 
Figure 2 
 
Based on the World Anti-Doping Agency (WADA) detection statistics from 2014, anabolic androgenic 
steroids (AAS) accounted for 48% of all adverse analytical findings of banned substances in competing 
athletes 
13
. With the wide range of performance-enhancing drugs available to athletes today, it is 
interesting that a significant proportion that chose to dope used steroids, which suggests that they offer 
benefits that other types of compounds do not. Unlike other classes of drugs, such as stimulants, which 
usually offer benefits only for as long as they remain active in the body, the effects of anabolic steroids can 
be long-lasting. Whilst the compounds themselves may no longer be present in the body, athletes can use 
these compounds to train; gaining muscle mass which will be retained for a period after steroid use is 
discontinued. Thus athletes retain the majority of the benefits without putting themselves at risk of being 
caught during in-competition screening. This provides the motivation for authorities to undertake out-of-
competition screening, and AAS are banned at all times by WADA in competing athletes. 
 
Anabolic steroids in equine sports 
In contrast to the well-documented advantages that anabolic steroids offer to human athletes, the effects 
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of anabolic steroids in equine competitors are not well-established 14. A study has shown that short-term 
nandrolone administration increased the glycogen content of post-exercise muscle tissue 15, however this is 
in contrast with two studies that found no observable changes resulting from nandrolone administration 
16,17. It has been shown that steroid administration delayed closure of epiphyseal growth plates in 
standardbreds, and suggested that this could lead to a potential increase to the long-term risks of injury 
during training 14. Additionally, it has been suggested that testosterone may not be involved in muscle 
development or maintenance in horses, as horses that experienced weight loss from maladaptation to 
training were observed to have similar testosterone levels compared to a control group 18. Aggressive 
behavioural changes resulting from anabolic steroid administrations have been noted 14,16 which could lead 
to more competitive horses that perform better in training and competition, however they may also lead to 
injury and accidents with other horses, riders or trainers. Nonetheless, even if the evidence for anabolic 
steroids acting as performance-enhancing substances in horses is currently unclear, there is clear evidence 
that anabolic steroid misuse can result in serious animal health and welfare consequences 14. These 
concerns, as well as the overwhelming evidence of the effects of anabolic steroids (including designer 
steroids) in other species (including humans) more than warrant their banning in competitive equine sports 
by IFHA 10. 
 
Designer anabolic steroids 
Since the first synthesis of testosterone over 80 years ago 19, there has been substantial work aiming to 
produce steroid compounds with differing and useful biological properties. During the so-called “golden 
age” of steroid research during the 1950-60s, numerous potent analogues of testosterone were 
synthesised some of which were published 20–24 whilst others were patented. The majority of these 
compounds however were only briefly tested for their anabolic activity and were never subsequently 
evaluated through clinical testing or approved for sale. As a result, they were forgotten, and then 
subsequently rediscovered in the past decade where they have been exploited by chemists who would seek 
to use the knowledge in the older steroid literature and bring these compounds to market in a clandestine 
fashion. 
 
Figure 3 
 
The term “designer steroid” can be defined as any anabolic steroid which has been prepared to 
intentionally evade detection by anti-doping laboratories. This typically involves chemical modification to 
the steroid core. The term itself was first coined in 2002 where Catlin et al. reported the first instance of a 
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designer anabolic steroid compound detected in an athlete’s urine 25. This designer steroid was 
norbolethone (18β-homo-17β-hydroxy-19-nor-17α-pregn-4-en-3-one), a synthetic anabolic steroid 
compound first synthesised in 1966 and subsequently found in clinical studies to be a highly potent 
anabolic agent 25,26, but which had never been approved for clinical use. Two years later, the same group 
detected tetrahydrogestrinone (18β-homo-17β-hydroxy-19-nor-17α-pregna-4,9,11-trien-3-one; THG) 
another designer steroid, following analysis of a spent syringe containing an allegedly undetectable 
anabolic steroid which was provided anonymously to the United States Anti-Doping Agency (USADA) by a 
former sporting coach 27–29. A third designer steroid, madol (17α-methyl-5α-androst-2-en-17β-ol; 
desoxymethyltestosterone), was also detected in a crude oily preparation received by the laboratory in 
2005 30. A transdermal preparation called “The Cream” was also identified, which contained a mixture of 
testosterone and epitestosterone in a controlled ratio. At this time the testosterone-epitestosterone ratio 
(T/E ratio) was an important marker used within WADA laboratories to identify samples suspected of 
doping with testosterone, and application of “The Cream” provided an increase in testosterone levels 
without altering the T/E ratio, making it harder to detect 31. These preparations were subsequently found in 
an investigation by the United States Federal Government to have been distributed by the Bay Area 
Laboratory Co-Operative (BALCO) alongside other anabolic steroids and performance enhancing substances 
in a secret program that supplied elite athletes with “undetectable drugs” to provide a competitive 
advantage 31. Although BALCO is now defunct, its legacy has changed the way anti-doping laboratories must 
approach the problem of anabolic steroid abuse in the world today. 
 
Despite an increase in awareness and research to combat designer steroid misuse, their usage is becoming 
more widespread, in part due to the ease in which these compounds can be obtained. These compounds 
are typically present in “dietary” or “nutritional” supplements which are widely marketed online and often 
contain unusual structures and substitution patterns that may render them more difficult to detect by 
existing analytical methods. These supplements are also often discontinued and replaced by new products 
when they become detectable by anti-doping laboratories or law enforcement. These structural changes to 
the core steroid structure also help suppliers evade legal restrictions and penalties regarding their 
manufacture and sale in some jurisdictions 32,33. As a result, these designer anabolic steroids pose a number 
of problems. They are often prepared in a clandestine fashion and as a result there is often minimal data 
available detailing the purity, safety or efficacy of these products. Users are forced to rely on advice from 
other users reporting their outcomes in online forums, or as is common, to experiment on themselves. This 
environment also encourages underreporting of side-effects and health complications, often with serious 
consequences 34. This is compounded by another major problem in that the labelling detailing the contents 
of these products is often falsified or omitted in an attempt to circumvent their control by law-enforcement 
32,33. This can hinder the work of health practitioners who are required to treat any complications that may 
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arise from supplement usage 34, and also prevent customs or border authorities from identifying potentially 
dangerous or illicit materials that may be entering their jurisdiction. With their widespread use by human 
athletes, it is highly likely that the problem of designer steroid misuse will find its way into the realm of 
equine sports as well. 
Equine steroid metabolism  
An understanding of the metabolism of anabolic steroid compounds is essential to develop methods for the 
detection of these compounds in equine sports. Anti-doping analysis typically requires the detection of 
known steroid markers and metabolites, as the parent compounds are often rapidly metabolised after 
administration. As such these metabolites form the basis of the majority of anti-doping screening protocols 
currently in use today. These metabolites are typically confirmed through the use of reference materials, 
which are pure compounds used as a positive control in analytical methods to confirm instances of anabolic 
steroid misuse. The identification of metabolites with reference materials involves comparison of the 
chromatographic retention time, mass spectrometry or other behaviour of the reference material to the 
identified metabolite, through a set of standardised criteria 35. A limitation of this approach however lies in 
the need for knowledge of the metabolite structure in order to provide a suitable material for comparison. 
This is particularly important in the case of designer steroids where the structures of the metabolites may 
not be known, or the reference materials may not be available.  
 
Steroid metabolites have historically been identified from urine, due to the relative ease of which samples 
can be obtained from competing animals, as well as the higher concentrations of drugs and drug 
metabolites that may be present. In recent times, blood samples have become another valuable biological 
matrix to detect steroid misuse, although this is less common due to the invasive sample collection 
required. Hair 36–38, faeces 39, and saliva 7 can also be used for the detection of drug compounds, and these 
matrices find use in anti-doping laboratories in some jurisdictions. 
 
Steroid metabolism typically proceeds by two complementary pathways, named phase I and phase II 
metabolism. By definition these are two distinct metabolic pathways, and although they commonly occur in 
concert, they are known to occur independently as well. Phase I metabolic processes typically involve 
functional group manipulations such as hydrolysis, oxidation, reduction, or hydroxylation. Metabolism 
primarily occurs on the steroid A and D-rings, although if these positions are inaccessible (as is often the 
case in designer steroids) then the B- and C-rings can be metabolised 39,40. Of particular interest to the 
equine metabolism of anabolic steroid compounds is the tendency for C3-ketone reduction, and C16-
hydroxylation to occur, particularly if the C17-position is alkylated 39. Additionally, A-ring metabolism is 
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commonly inhibited through extended conjugation as is seen in the case of the steroid trenbolone (17β-
hydroxyestra-4,9,11-trien-3-one) which produces multiple hydroxylated metabolites 39. The phase I 
metabolism of these compounds can also have an effect on their biological activity, as it has been reported 
in androgen bioassay studies that the metabolism of anabolic steroids can either activate or deactivate the 
steroid molecule 33,41. 
 
Phase II metabolism involves the conjugation of highly polar groups to the steroid metabolites. The 
conjugation of small, charged or highly polar compounds to the hydrophobic steroid backbone confers an 
increase in the aqueous solubility of these compounds, allowing for their rapid and efficient excretion via 
the urine. The two main phase II steroid conjugation pathways are glucuronylation and sulfation; steroid 
glucuronide metabolites form via enzyme-mediated transfer of glucuronic acid from a uridine diphosphate 
(UDP) glucuronic acid donor, while steroid sulfate metabolites form via enzyme-mediated transfer of 
sulfate from a 3'-phosphoadenosine-5'-phosphosulfate (PAPS) donor 40. Minor conjugates of other small 
molecules are also known including phosphate, sugars, and amino acids 42,43, although they are considered 
minor components in anti-doping analysis and are not routinely investigated. Although phase II conjugates 
are the primary components identified from urine, unconjugated metabolites can also be observed. 
Conjugation can also occur in the absence of phase I metabolism if metabolism is hindered, or if the 
compound already possesses suitable functionality 40.  
 
In vitro equine steroid metabolism 
Since anti-doping analysis requires knowledge of the metabolites that indicate steroid misuse, the 
metabolism of each steroid must be studied in order to determine which metabolites(s) may be the most 
suitable markers for detection. In vivo administration is a staple method for the study of steroid 
metabolism, however in vitro methods are gaining popularity 39. Additionally, the Association of Official 
Racing Chemists (AORC) criteria currently allow for the use of in vitro-derived materials as standards for 
confirmatory analysis 35, providing additional motivation for developing in vitro systems to model equine 
steroid metabolism. The key concern regarding the use of in vitro methods is how accurately they reflect 
the metabolism observed in vivo and for this reason they typically accompany administration studies to 
allow comparison between in vivo and in vitro systems.  
 
In order to model the liver, which is the principle organ involved in detoxification and metabolism of 
exogenous substances, preparations involving liver metabolic enzymes are amongst the most commonly 
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used in vitro methods 29,44–50. Equine liver microsomes and S9 fraction are most commonly used to model 
equine metabolism due their ease of use and commercial availability. These enzymes are typically 
supplemented with a number of biological co-factors, including nicotinamide adenine dinucleotide (NADH), 
or nicotinamide adenine dinucleotide phosphate (NADPH) in order to promote the metabolic reactions. 
Most systems use an excess of these reagents 44,48, although systems have been developed which employ 
co-factor regeneration, in which a NADH/NADPH-generating reaction is coupled to the NADH/NADPH-
dependant metabolic reactions. Typically, the reaction of glucose-6-phosphate with a glucose-6-phosphate 
dehydrogenase (G6PDH) enzyme is used, which regenerates NADH/NADPH as a by-product of oxidation. 
This allows for the use of a catalytic amount of these co-factors in the metabolism reaction 29,45,46,51. Recent 
reports have also demonstrated the practicality of using homogenised whole liver tissue to perform in vitro 
studies, in an effort to closely replicate in vivo metabolism 51–53. These studies have even demonstrated the 
ability to generate phase II metabolites without the use of expensive phase II co-factors such as UDP-
glucuronic acid or PAPS 53. The limitations of this approach are reflected in the sample preparation of the 
whole liver extracts, as well as potential variations in the metabolic profile due to the use of individual 
tissue donors. Other approaches to model equine metabolism involve microbial systems which are typically 
based on equine faecal bacteria, and although these are currently largely unimportant for modelling equine 
steroid metabolism in an anti-doping context, they may be important in other areas 54–58.  
Anti-doping screening for designer anabolic steroids 
Historically, steroid metabolites have been detected in analytical samples by thin layer chromatography 
coupled to ultra-violet detection (TLC-UV) 59. This was largely superseded by the development of high 
performance liquid chromatography-ultraviolet detection (HPLC-UV) which was popular until the 1980-
1990’s, although it still finds use in specialised anti-doping applications 39. With the development of gas-
chromatography coupled to mass spectrometry (GC-MS), these instruments became the method of choice 
in anti-doping laboratories 8. A range of other techniques have become available and occasionally find use 
in anti-doping laboratories alongside existing methods. Biological assays 8,60–65 can be used to detect doping 
directly from samples. For example, if a sample gave a positive result from an androgen receptor assay or 
immunoassay, it may indicate that anabolic agent(s) are present in the sample which would warrant further 
testing. In most cases, these bioassay techniques can be sufficiently general to allow for detection of 
certain steroid classes or highly specific for certain steroid compounds, although they often do not provide 
an opportunity to confirm the identity of any detected compounds 62. Building on this idea, metabolomics 
approaches are also gaining popularity as they allow for the high-throughput detection of minor variations 
of a very large number of biomarkers in response to drug administration 66, making it extremely difficult to 
hide instances of steroid misuse. Nuclear magnetic resonance spectroscopy (NMR) occasionally finds use in 
anti-doping laboratories as it can be used to unequivocally determine metabolite structure, however is 
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severely limited in most cases as it requires extensive sample purification and large sample volumes to be 
effective 39.  
 
Whilst GC-MS has been the mainstay for analytical laboratories, in recent years there has been a movement 
towards liquid-chromatography coupled to mass spectrometry (LC-MS) which offers several advantages 
over GC-MS analysis 8. GC-MS requires often laborious sample preparation including purification, hydrolysis 
of the phase II urinary conjugates, and chemical derivatisation to a more volatile species prior to analysis. 
Trimethylsilyl (TMS) ethers or other silyl derivatives are among the derivatives most widely used in 
laboratories due to their stability, ease of preparation, and characteristic fragmentation patterns 67. In 
contrast, LC-MS analysis has the advantage of not requiring these preparatory steps allowing much higher 
throughput in sample analysis. Additionally, LC-MS allows the direct detection of intact phase II conjugates, 
which may offer advantages in the detection of some steroid compounds which are primarily excreted as 
these conjugates and that may otherwise only be detected indirectly by GC-MS methods after hydrolysis 
and derivatisation 8,46,68. LC-MS is not a complete replacement for GC-MS however, as the analysis of some 
compounds is difficult with LC-MS, including the study of saturated steroids and steroid diols, which ionise 
poorly under the electrospray ionisation (ESI) and atmospheric-pressure chemical ionisation (APCI) 
conditions common to LC-MS systems 8,39. Additionally, the characteristic fragmentation patterns observed 
using electron ionisation (EI) common to GC-MS systems may often provide more diagnostic information 
about metabolite structure compared to the softer ionisation techniques common to LC-MS 8. However, 
the high energy used in EI methods which result in these characteristic fragments may also result in 
reduced sensitivity as the parent structure is heavily fragmented. Regardless, both analytical methods 
afford their own distinct advantages and anti-doping laboratories should make use of the strengths of both 
these techniques for the efficient screening of AAS misuse. 
 
Recent advances in modern instrumentation which allow tandem MS experiments (MSn) afford a greater 
ability to detect and identify metabolites. This is due to the ability of these systems to perform a multitude 
of scan types including: full scan MS, multiple reaction monitoring (MRM), product-ion or precursor-ion MS, 
or neutral loss experiments. This is in contrast to older technologies which often rely on full-scan and 
single-ion monitoring (SIM) techniques in order to achieve the required sensitivity for detection. 
Additionally, the recent development of affordable liquid-chromatography high resolution accurate mass 
spectrometry (LC-HRAM) technologies has greatly assisted anti-doping laboratories. Data obtained with 
these systems is of very high quality and at sufficient mass resolution that minute differences in molecular 
composition can be detected 69. The increase in specificity is afforded through the use of a much narrower 
mass window (±10-15 ppm) for mass detection compared to standard triple quadrupole detection (±1 Da). 
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As a result, this can allow laboratories to undertake retrospective analysis of newly-identified compounds 
in historically acquired data, allowing detection of previously unidentified compounds. 
 
The most recent advances in anti-doping research come from new developments in “untargeted” or “open” 
screening methods. Such methods typically attempt to screen for characteristic fragments, or 
fragmentation modes (such as characteristic neutral losses) of steroid compounds, rather than the steroid 
compound itself 70–73. This would prevent minor structural changes to a molecule which results in a change 
of the molecular mass from rendering a compound undetectable, and highlight the need for follow-up 
testing to identify the new target compound. Another promising advancement is the Equine Biological 
Passport (EBP) 74, which mirrors the Athlete Biological Passport (ABP) maintained by WADA for human 
athletes 75. The EBP would longitudinally monitor the concentration of certain biological compounds in the 
horse, and allow for the detection of changes in these levels in response to anabolic steroid misuse. This 
would require frequent testing to establish the steroid profile of the individual animal, and future instances 
of steroid misuse could be detected through changes to the established profile. Such an approach would 
assist greatly in establishing relevant threshold levels for endogenous compounds, as well as assisting in the 
detection of designer anabolic steroids. Although there are a number of technical and administrative 
hurdles to overcome before this can be fully realised, this approach has the potential to effectively combat 
the misuse of drugs in equine sports. Such methods are likely to be essential to combat the rapid increase 
of designer steroids, and other unknown compounds into the future. 
 
Equine metabolism of designer steroids 
The metabolism of all anabolic androgenic steroid compounds in horses is far beyond the scope of this 
review, however a substantial summary can be found in several reviews by Scarth et al. 76 (endogenous 
anabolic steroids in horses and other animals), Teale and Houghton 77 and Houghton et al. 78 (phase I and II 
metabolism studies of some common synthetic steroids marketed as pharmaceuticals), and Scarth et al. 39 
(a comprehensive review of drug metabolism in horses). Instead the purpose of this review is to explore 
recent advances in the study of designer anabolic steroids as well as other anabolic steroids present in 
many of the dietary supplements available online, which have not been covered in previous reviews. A 
summary of the metabolism of these compounds in equine systems in presented below. The designer 
steroids desoxyvinyltestosterone 79, and estra-4,9-diene-3,17-dione 80 have been studied in equine systems 
as reviewed by Scarth et al. 39, and are included only briefly in this work. 
Table 1: Summary of the equine metabolism of designer steroids 
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11-Adrenosterone (androst-4-ene-3,11,17-trione) 
Figure 4 
 
In humans, 11-adrenosterone is an endogenous steroid produced predominately in the adrenal cortex that 
exerts a mild anabolic effect 81. It has been reported as a component of dietary supplements such as 
11-OXO (ErgoPharm) 81 and is marketed as a “selective cortisol modulator” rather than as an anabolic 
agent. It is a known inhibitor of the enzyme 11β-hydroxysteroid dehydrogenase type 1, which is required 
for the formation of cortisol from cortisone 81. Inhibition of cortisol biosynthesis may offer athletes a 
competitive advantage as cortisol itself is involved in a range of biological processes including fat and 
protein metabolism, regulation of the immune system, and responding to stress 81–83. The endogenous 
concentrations of this compound in the horse is currently unknown, however based on a previously 
reported human in vivo administration 81 it has been suggested that a 11β-hydroxyandrosterone threshold 
of greater than 10 µg/mL, or a 11β-hydroxyandrosterone:11β-hydroxyetiocholanolone ratio of greater than 
20:1, or the use of GC/IRMS may be indicative of 11-adrenosterone misuse 44. 
 
The equine metabolism of 11-adrenosterone has only been studied by in vitro methods 44. Following 
metabolism with equine liver microsomes and S9 fraction, one major reduced metabolite was observed by 
LC-MS/MS. Minor metabolites were also observed including: one minor reduced metabolite, one direduced 
metabolite, one trireduced metabolite, two hydroxylated metabolites, and one reduced and hydroxylated 
metabolite. Metabolites were tentatively assigned structures based on analysis of their LC-HRAM product-
ion spectra. An additional major reduced metabolite was observed by GC-MS/MS. Although the 
endogenous nature of 11-adrenosterone in humans has been established, it is currently unclear if this 
compound is endogenous in horses. Older studies have proposed 11-adrenosterone as a metabolite of 
cortisol in the synovial fluid of human and equine knee joints after administration of cortisol 84, however no 
studies have identified it directly. Due to its potential endogenous nature, a threshold approach may be 
required in order to confirm misuse of this compound.  
 
ATD (androsta-1,4,6-triene-3,17-dione) 
Figure 5 
 
ATD is an aromatase inhibitor that has been reported as a component of dietary supplements including 
Attitude (SAN Nutrition) 85 and Novedex XT (Gaspari Nutrition) 2,86. Aromatase inhibitors irreversibly and 
covalently bind to the active site of the P450 enzyme aromatase, which is essential in the conversion of 
androgens into estrogens in vivo 87,45. Inhibition of this enzyme can be used to limit the endogenous 
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conversion of androgens such as testosterone into estrogens, in turn increasing the concentration of AAS in 
the body. Although aromatase inhibitors have legitimate therapeutic applications such as in the treatment 
of human breast and ovarian cancers 45,88, they can be exploited to gain muscle mass as they can increase 
the effects of endogenous or co-administered anabolic steroids. They can also potentially alleviate some of 
the side effects of anabolic steroid misuse 45,89. 
 
The equine metabolism of ATD has been studied by in vitro methods 44. Following metabolism with equine 
liver microsomes and S9 fraction, two reduced metabolites (tentatively assigned as C17-isomers), and one 
reduced and hydroxylated metabolite (tentatively assigned as C15, or C16-hydroxylated) were identified. 
Minor metabolites including three direduced metabolites, three hydroxylated metabolites, five additional 
reduced and hydroxylated metabolites, and three hydroxylated and direduced metabolites were also 
observed. The structures of the major metabolites were tentatively assigned based on their LC-HRAM 
product-ion spectra. In addition, one of the direduced metabolites was identified as boldenone (17β-
hydroxyandrosta-1,4-dien-3-one) by comparison to a reference material. The authors recommend analysis 
by LC-MS over GC-MS due to the detection of several C19-nor steroid artefacts that resulted from TMS 
derivatisation prior to GC-MS analysis 44,90, and also due to the higher sensitivity of detection by LC-MS. 
 
The metabolism of ATD has also been studied in vivo by a controlled oral administration (800 mg, 2 
thoroughbred geldings) 51. Following phase I metabolism, fourteen metabolites were identified by LC-HRAM 
analysis including: three reduced metabolites (two C17-reduced and C1-C2 reduced), three direduced 
metabolites (C1-C2 and C17-direduced, C1-C2 and C3-direduced, and boldenone), four reduced and 
hydroxylated metabolites, and four direduced and hydroxylated metabolites (two C5-C6 and C17 direduced 
with C16-hydroxylation, and two C1-C2 and C17-direduced and hydroxylated metabolites). A number of 
these were matched to reference materials. The identities of the phase I metabolites not matched to 
standards were tentatively assigned by analysis of the LC-HRAM product-ion spectra. The position of 
hydroxylation in these metabolites was not assigned where standards were not available, although the 
authors comment on the presence of MS fragments at m/z 149 and 167 being characteristic of D-ring 
hydroxylation which suggests C16-hydroxylation as a major pathway in the metabolism of these 
compounds 39,51. A pair of metabolites resulting from C1-C2 and C17-direduction and hydroxylation were 
observed that had not been previously detected in human studies 86. Elevated levels of testosterone were 
also observed which were above the threshold levels required for a positive testosterone doping result. 
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Phase II metabolites were observed directly as a mixture of sulfate and glucuronide conjugates, and a 
minority were identified by comparison to the products generated from in vitro metabolism with 
homogenised horse liver 35. Phase II metabolites were also identified indirectly by hydrolysis of the 
fractionated glucuronide and sulfate metabolites. Parent ATD was excreted primarily unconjugated, whilst 
one C17-reduced metabolite was identified as the sulfate conjugate, and the remaining C17-reduced 
metabolite as the glucuronide conjugate. The authors comment that the C17-glucuronide is likely to be the 
C17α-stereochemistry, which agrees with observations reported by many as summarised by Scarth et al. 39. 
Sulfate conjugates were also identified for boldenone, and for the C1-C2 and C17-direduced metabolite 
which were tentatively assigned C17β-stereochemistry. Glucuronide conjugates were observed for the C1-
C2 and C3-direduced, and both two C5-C6 and C17 direduced and hydroxylated metabolites. The remaining 
metabolites were observed as mixtures of both sulfate and glucuronide conjugates. Some metabolites were 
identified up to 77 hr post-administration, and the authors recommend 17β-hydroxyandrosta-1,4,6-trien-3-
one, and 17β-hydroxyandrosta-4,6-dien-3-one as potential target analytes for screening due to their long 
detection windows, and commercial availability.  
 
As a part of this study, a comparative phase I in vitro metabolism was performed using homogenised 
equine liver. Twelve of the metabolites observed in vivo were identified in vitro in addition to both boldione 
(androsta-1,4-diene-3,17-dione) and epiboldenone (17α-hydroxyandrosta-1,4-dien-3-one) which were 
identified by comparison to reference materials. Interestingly, elevated levels of testosterone were not 
observed in vitro suggesting that testosterone is not a direct metabolite of ATD but rather a result of 
aromatase inhibition. These results, along with the in vivo study agree well with the previously discussed in 
vitro study reported by Clarke et al. 44. 
 
3α-Chloro-17α-methyl-5α-androstan-17β-ol 
Figure 6 
 
3α-Chloro-17α-methyl-5α-androstan-17β-ol is an anabolic steroid containing C3-chlorination, which was 
identified alongside the 3β-chloro isomer (5:2 mixture) in red-and-black capsules containing white powder 
seized in 2012 by law-enforcement in Queensland, Australia 29. This compound had not been previously 
reported in the literature, and it appears to be the first instance of a C3-halogenated anabolic steroid 
intended for doping purposes.  
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Owing to concerns about its chemical reactivity and potential toxicity, this compound was only studied 
using in vitro systems 29. Yeast, HEK293 and HuH7 androgen receptor bioassays have found the potency of 
the major 3α-chloro isomer to be similar to testosterone (87-147% potency), whilst the 3β-isomer gave 
much lower potency (2-9%). Acute cellular toxicity was not observed in yeast and HEK293 cell lines. In vitro 
metabolism studies on the 3α-isomer using human and equine liver S9 fraction identified differences in 
metabolism which may be useful for doping control. Equine in vitro metabolism afforded 3α-chloro-17α-
methyl-5α-androstane-16α,17β-diol as the sole observed metabolite, the structure of which was matched 
against synthetic reference material. The relative abundance isotope pattern of 35Cl and 37Cl (3:1) confirmed 
retention of C3-chlorination in the equine metabolite. The stereochemistry of the C16-hydroxylation was 
supported by 1H NMR, and the failure to form a C16-C17 cis-acetonide derivative, with the C16α-C17α-
isomer used as a control to demonstrate the efficiency of the transformation. Human in vitro metabolism 
afforded 17α-methyl-5α-androstane-3α,17β-diol, lacking C3-chlorination, which was not observed in the 
equine system. This metabolite was confirmed by comparison to both the 3α-hydroxy and 3β-hydroxy 
reference materials, and is a known metabolite of a number of other methylated anabolic steroid 
compounds such as methyltestosterone, and mestanolone (17β-hydroxy-17α-methylandrostan-3-one) 39. 
As such this metabolite is likely detectable by existing methods. The authors recommend laboratories 
monitor for the 3α-chloro-17α-methyl-5α-androstane-16α,17β-diol, and 17α-methyl-5α-androstane-
3α,17β-diol metabolites in routine screening to detect the misuse of this compound. 
 
Halodrol (4-chloro-17α-methylandrosta-1,4-diene-3,17β-diol) 
Figure 7 
 
Halodrol is a 4-chlorinated steroid structurally similar to clostebol (4-chloro-17β-hydroxyandrost-4-ene-3-
one), and turinabol (4-chloro-17β-hydroxy-17α-methylandrosta-1,4-diene-3-one) 39,44 which has been found 
in a variety of dietary supplements such as Halodrol (Gaspari Nutrition), Zeus (BioArmor) and Iron Dragon 
(BioArmor). These supplements typically list only the 3β-hydroxy isomer on their labelling but usually 
contain a mixture of both stereoisomers.  
 
The equine metabolism of this compound has only been studied using in vitro systems 44. A mixture of 
halodrol isomers (3:2, α:β) was subjected to phase I metabolism using both equine liver microsomes and S9 
fraction. Metabolism identified the C3-oxidised metabolite (turinabol) and three oxidised and hydroxylated 
metabolites as major metabolites. Minor metabolites were observed including, two A-ring reduced and C3-
oxidised metabolites, one hydroxylated metabolite, one A-ring reduced and hydroxylated metabolite, two 
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additional oxidised and hydroxylated metabolites, one dihydroxylated metabolite, one reduced and 
dihydroxylated metabolite, one direduced and dihydroxylated metabolite, and two oxidised and 
dihydroxylated metabolites. Metabolites were tentatively assigned based on their LC-HRAM, or GC-MS/MS 
product-ion spectra. The parent compounds (3α/β,17-diols), and the major oxidised and hydroxylated 
metabolites were reported to ionise poorly under APCI conditions which are commonly used for LC-MS 
analysis, however ionised well under GC-MS (+EI) conditions after TMS derivatisation. There were minor 
differences reported between the two metabolism systems used, with equine liver S9 appearing to give 
more of the major metabolites, which the author suggested may highlight the importance of cytosolic 
enzymes in the metabolism of these compounds. The predominate product was the C3-oxidised 
metabolite, which corresponds to the synthetic anabolic steroid turinabol, which has been previously 
studied in vivo in the horse 39,91. A number of the key metabolites of halodrol reported in this study match 
those reported for the in vivo metabolism of turinabol. As such, the authors recommend that monitoring 
for turinabol misuse would likely be suitable for the detection halodrol misuse. 
 
20-Hydroxyecdysone (2β,3β,14α,20β,22α,25-hexahydroxy-5β-cholest-7-en-6-
one) 
Figure 8 
 
20-Hydroxyecdysone is an ecdysteroid hormone which is present naturally in numerous invertebrate and 
plant species. It is essential for moulting and reproduction in many arthropod species, and is also present as 
an insecticide in some plant species where it disrupts the development of insect pests that would feed 
upon them 92. Reports in the older steroid literature have suggested that ecdysteroids may exert a small 
anabolic effect in several mammal species 92, although more recent studies offer conflicting reports of their 
anabolic effects 93,94. Nonetheless, 20-hydroxyecdysone has been found in dietary supplements such as 
Oxybolin 250 (High-Tech Pharmaceuticals) and Ecdy-Bolin (Truly Huge Supplements). These supplements 
are often marketed as “natural”, “plant-based”, or “low-testosterone” alternatives to other anabolic 
steroid-containing body-building supplements. Whilst it is unclear whether supplements containing 20-
hydroxyecdysone would offer a competitive advantage, they are currently banned in competition IFHA 10. 
 
The equine metabolism of 20-hydroxyecdysone has only been studied by in vitro methods 44. Only the 
parent compound was observed after incubation with equine liver microsomes and S9 fraction. GC-MS/MS 
analysis afforded a complex mixture of partial derivatisation products and no characteristic fragmentation 
information, likely due to the multiple potential sites for silylation. It is known that complete silylation of 
related ecdysteroid compounds is slow, due to the hindered tertiary hydroxyl groups C14 and C20, with 
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optimal silylation occurring only after extended reaction times 95. Related ecdysteroid compounds are 
known to be rapidly excreted with only minor metabolic changes in humans 92,95 which could rationalise the 
lack of phase I metabolism observed in this study. The authors also suggest that phase I metabolism was 
expected to be a minor pathway compared to the phase II metabolism that would predominate in vivo and 
was not investigated as a part of this study. They also raise concerns over potential accidental dietary 
consumption through animal feed, as ecdysteroid compounds are known to be present in many plant 
species 92 , potentially requiring a threshold approach for detection. The authors also observed minor levels 
of desoxy-, dehydro-, and hydroxy-metabolite impurities in their control in vitro incubations, suggesting the 
presence of these minor components in the commercial 20-hydroxyecdysone preparation. This could call 
into question other studies which identify these as metabolites 95,96. The authors recommend monitoring 
for the unconjugated parent compound, or its likely phase II conjugates for the detection of 20-
hydroxyecdysone misuse. 
 
Formestane (4-hydroxyandrost-4-ene-3,17-dione) 
Figure 9 
 
In human medical practice, formestane is a pharmaceutical aromatase inhibitor which irreversibly and 
covalently binds to the active site of the P450 enzyme aromatase 45. After an adverse analytical finding in 
2011, the endogenous nature of formestane in horses was investigated after concerns were raised that it 
could potentially be a metabolite of androst-4-ene-3,17-dione, an intermediate in testosterone 
biosynthesis 45,76. Additionally, it is a potential metabolite of 4,17β-dihydroxyandrost-4-en-3-one. Analysis 
of the data obtained during routine screening for 269 equine urine samples showed that formestane was 
not present endogenously. Following this, an in vivo controlled oral administration study of formestane was 
undertaken (800 mg, 2 thoroughbred geldings) 45. 
 
After phase I metabolism, the parent compound as well as seven metabolites were identified as follows: 
one reduced metabolite (4,17β-dihydroxyandrost-4-en-3-one) which was matched to a reference material, 
two direduced metabolites (proposed as androst-4-ene-3α,4,17β-triol, and androst-4-ene-3β,4,17β-triol) 
which were matched to the products derived from partial reduction of formestane with sodium 
borohydride, and an additional four direduced metabolites (four of the possible 3,4-dihydroxy-5-androstan-
17-one metabolites) which were tentatively identified by comparison to literature data 89,97. Elevated levels 
of testosterone or other androgens not considered to be metabolites of formestane were not identified in 
this study. The structures of the phase II metabolites were determined through hydrolysis of the 
fractionated glucuronide and sulfate metabolites to their corresponding phase I metabolites. Formestane, 
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4,17β-dihydroxyandrost-4-en-3-one, and three of the 3,4-dihydroxy-5-androstan-17-one metabolites were 
excreted primarily as glucuronide conjugates, whilst androst-4-ene-3α,4,17β-triol, androst-4-ene-3β,4,17β-
triol, and the remaining 3,4-dihydroxy-5-androstan-17-one metabolite were excreted as a mixture of 
glucuronide and sulfate metabolites. In addition to identifying the key metabolites, the excretion profiles of 
formestane and 4,17β-dihydroxyandrost-4-en-3-one were studied. Peak excretions of 40-44 µg/mL and 7-
11 µg/mL respectively were observed at 5.6-6.3 hr post-administration, falling to below the limits of 
detection at 29 hr and 34 hr post-administration respectively. In addition, formestane was observed in 
plasma peaking at 6-10 hr post-administration, and falling below the limits of detection 34 hr post-
administration. No other formestane metabolites were observed in equine plasma. As a part of this study, a 
comparative in vitro study was also undertaken. Phase I metabolism using equine liver microsomes 
prepared from whole liver tissue afforded the parent compound and seven metabolites, identified as 
follows: 4,17β-dihydroxyandrost-4-en-3-one, five direduced metabolites (androst-4-ene-3α,4,17β-triol, 
androst-4-ene-3β,4,17β-triol, and three of the possible 3,4-dihydroxy-5-androstan-17-one metabolites), 
and one trireduced metabolite. The majority of the metabolites observed in vitro matched those observed 
in vivo after hydrolysis of the phase II conjugates.  
 
A separate in vitro study has also been performed by Clarke et al. 44, who identified a similar metabolite 
profile. LC-HRAM and GC-MS/MS analysis observed several hydroxylated metabolites, in addition to 
metabolites similar to those reported above. Metabolites were not identified by comparison to reference 
materials in this study, but instead were tentatively assigned by analysis of their MS data. Based on 
observations from both studies, the authors recommend monitoring for the parent compound and 4,17β-
dihydroxyandrost-4-en-3-one to detect formestane misuse. 
 
Furazadrol ([1',2’]isoxazolo[4’,5’:2,3]-5α-androstan-17β-ol) 
Figure 10 
 
Furazadrol is a derivative of dihydrotestosterone containing an isoxazole ring fused to the steroid A-ring. It 
has been reported as a component of dietary supplements such as Orastan-A (Gaspari Nutrition) 32 and 
Furazadrol (Axis Labs) 33 predominately as the tetrahydropyranyl ether. In both cases, these supplements 
had incorrect labelling of the content information 32,33. Furazadrol has been reported to exert anabolic 
activity in the older literature 21,98, and also in more recent yeast and human HuH7 androgen bioassays 33.  
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Following an equine in vivo controlled oral administration (200 mg, 1 thoroughbred gelding) 46, furazadrol 
was excreted primarily as the sulfate and glucuronide conjugates without phase I metabolism, which were 
detectable up to 24 hr post-administration by LC-HRAM analysis. Additional minor metabolites were also 
observed including a hydroxylated sulfate metabolite, two oxidised and hydroxylated sulfate metabolites, 
epifurazadrol glucuronide, and an oxidised and hydroxylated glucuronide metabolite. No unconjugated 
furazadrol metabolites were observed. The identity of furazadrol 17-sulfate, furazadrol 17-glucuronide, and 
epifurazadrol 17-glucuronide was confirmed by comparison to synthetic reference materials 99,100, and the 
identity of the other metabolites was tentatively assigned through analysis of the LC-HRAM product-ion 
spectra. The sites of hydroxylation for minor metabolites were not identified in this study. Further 
structural confirmation was performed through enzymatic hydrolysis of the fractionated sulfate and 
glucuronide metabolites, with analysis of the corresponding phase I metabolites as above. Hydrolysis of the 
sulfate fraction was achieved through use of Pseudomonas aeruginosa arylsulfatase, which is a purified 
enzyme with sulfatase activity and no alternative activities as are commonly found in commercial sulfatase 
preparations 101. This enzyme was observed to completely hydrolyse all the in vivo steroid sulfate 
metabolites identified in this study. The major urinary metabolites (furazadrol 17-sulfate and furazadrol 17-
glucuronide) were quantified in equine urine, to determine the detection window and limits of detection 
for these analytes. The authors recommend monitoring for these analytes or their hydrolysed phase I 
counterpart furazadrol for the detection of furazadrol misuse.  
 
As a part of this study, a comparative in vitro phase I metabolism study was also undertaken using equine 
liver S9 fraction. A number of the metabolites identified were reported to match those observed from the 
in vivo profile obtained after hydrolysis of the urinary sulfate and glucuronide conjugates. The major phase I 
markers were observed in this study, although the authors comment that the in vitro study was limited in 
its ability to mimic in vivo metabolism. Phase I metabolism identified a number of metabolites including 
epifurazadrol, oxidised furazadrol, eight hydroxylated metabolites, an oxidised and hydroxylated 
metabolite, and two dihydroxylated metabolites, which were confirmed by comparison to synthetic 
reference materials where available, or tentatively assigned through analysis of the LC-HRAM product-ion 
spectra. 
 
Methasterone (17β-hydroxy-2α,17α-dimethyl-5α-androstan-3-one) 
Figure 11 
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Methasterone is a dimethylated analogue of dihydrotestosterone, and the C17-methylated analogue of 
drostanolone. It has been reported in the older steroid literature to exert a strong anabolic effect in rats 
102,103, and predicted to be a potent anabolic agent in a more recent computational study 104. It has been 
reported as a component of the dietary supplements Superdrol (Anabolic Xtreme) 34, S-drol (Black China 
Labs) 105, and Methasterone (Legal Gear) 2. Methylated steroids such as these typically have the advantage 
of being orally bioavailable at the cost of higher toxicity to the liver and kidneys 39. As a dimethylated 
steroid, methasterone has additional risks and has been reported to be involved in a number of serious 
health complications in humans including cases of severe jaundice, and immunoglobulin A (IgA) 
nephropathy 34,106,107.  
 
The equine metabolism of methasterone has only been studied using in vitro methods 44. Following 
metabolism with equine liver microsomes and S9 fraction, two C3-reduced metabolites were the 
predominate metabolites identified. Additionally, two minor hydroxylated metabolites and six minor 
reduced and hydroxylated metabolites were also observed. Metabolites were tentatively assigned based on 
their GC-MS/MS product-ion spectra as LC-MS/MS analysis afforded poor ionisation efficiency for the 
target analytes. The authors consider the use of GC-MS/MS essential for the detection of the two reduced 
metabolites (2α,17α-dimethyl-5α-androstane-3α/β,17β-diol) which may indicate methasterone misuse. 
 
Oxyguno (4-chloro-17β-hydroxy-17α-methylandrost-4-ene-3,11-dione) 
Figure 12 
 
Oxyguno is an analogue of clostebol and 11-adrenosterone, and contains C17-methylation typical of orally 
bioavailable anabolic steroids 39. It has been reported as a constituent of the dietary supplement Oxyguno 
(Spectra Force Research) 33,47,69 and has been reported in the older steroid literature to exert significant 
anabolic activity 108, as well as more recently in yeast, human HEK293, and human HuH7 androgen 
bioassays 33.  
 
Following an equine in vivo controlled oral administration (52.5 mg twice daily for 2 days, 2 thoroughbred 
geldings) 47, oxyguno has been reported to be excreted as a range of unconjugated, sulfate-conjugated and 
glucuronide-conjugated metabolites which were detectable up to 12 hr post-administration. After phase I 
metabolism, the parent compound as well five novel metabolites were identified as follows: two C11-
reduced metabolites, a C3 and C4-direduced metabolite, a C20-hydroxylated metabolite with C3, C4 or C11-
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direduction, and C17-epi-oxyguno. The identities of these metabolites were tentatively assigned by analysis 
of their GC-MS/MS product ion spectra. The two C11-reduced metabolites and the hydroxylated and 
direduced metabolite were observed as glucuronide conjugates, whilst the C3 and C4-direduced metabolite 
was observed as both glucuronide and sulfate conjugates. The C17-epi-oxyguno metabolite was observed 
to arise from the sulfate conjugate. Epimerisation at the tertiary centre is a known metabolic pathway in 
C17-methylated steroids, and occurs via hydrolysis of a tertiary sulfate metabolite 109–111. The tentative 
identities of these metabolites were established by LC-HRAM analysis of the intact conjugates, with further 
structural confirmation afforded by GC-MS/MS analysis of the enol-TMS ether derivatives obtained from 
the hydrolysis of the fractionated glucuronide and sulfate metabolites. The excretion of free oxyguno was 
also quantified to establish an elimination profile and determine a suitable detection window. Excretion 
peaked at 1-3 h and 2 h in blood and urine respectively, and fell below the limit of detection at 7 h and 12 h 
respectively. The authors recommend monitoring for the parent compound, or the direduced metabolite 4-
chloro-3,17β-dihydroxy-17α-methyl-5α-androstan-11-one for the detection of oxyguno misuse. 
 
As a part of this study, a comparative in vitro study was also undertaken. Phase I metabolism using equine 
liver microsomes prepared from whole liver tissue afforded four primary metabolites including two C11-
reduced metabolites, a C20-hydroxylated metabolite, and a C20-hydroxylated metabolite with C11-
reducion. The tentative identities of these metabolites were established by analysis of the GC-MS product-
ion spectra of the enol-TMS ether derivatives of the in vitro metabolites. The major C11-reduced 
metabolites were reported to be identical to the C11-reduced metabolites observed after hydrolysis of the 
in vivo samples. The metabolic profile generated by in vitro techniques did not agree well with the in vivo 
profile. Only two of the five in vivo metabolites were identified, and the recommended screening marker 
4-chloro-3,17β-dihydroxy-17α-methyl-5α-androstan-11-one was not observed, suggesting this in vitro 
method may be limited in its ability to predict in vivo results.  
 
Δ1-Testosterone (17β-hydroxy-5α-androst-1-en-3-one) 
Figure 13 
 
Δ1-Testosterone is a synthetic anabolic steroid which closely resembles the structure of testosterone, 
substituting the C4-C5 double bond for a C1-C2 double bond. It can also be viewed as a 5α-reduced form of 
boldenone, another anabolic steroid which is well-known for its abuse in sports 39. It has been reported to 
be a component of dietary supplements such as 1-androsterone (Advanced Muscle Science) and 1-AD 
(ErgoPharm) which typically contain Δ1-testosterone in addition to one or more of the following 
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compounds: 5α-androst-1-ene-3,17-dione, 5α-androst-1-ene-3,17-diol, or 3β-hydroxy-5α-androst-1-en-17-
one, all of which are metabolised to Δ1-testosterone in vivo 112,113.  
 
Following an equine in vivo controlled oral administration (800 mg, 2 thoroughbred geldings) 114, Δ1-
testosterone has been reported to be excreted as a range of unconjugated, sulfate-conjugated and 
glucuronide-conjugated metabolites which were detectable up to 72 hr post-administration. After phase I 
metabolism, the parent compound as well as eight metabolites were identified as follows: four reduced 
metabolites (5α-androst-1-ene-3α,17β-diol, 5α-androst-1-ene-3β,17α-diol, 5α-androst-1-ene-3β,17β-diol, 
and epiandrosterone (3β-hydroxy-5α-androstan-17-one)), three doubly reduced metabolites (5α-
androstane-3β,17β-diol, 5α-androstane-3α,17α-diol, and 5α-androstane-3β,17α-diol), and one 
hydroxylated metabolite. The parent compound, 5α-androst-1-ene-3α,17β-diol, and the hydroxylated 
metabolite were found to be excreted primarily as sulfate conjugates, whilst 5α-androst-1-ene-3β,17α-diol 
and 5α-androst-1-ene-3β,17β-diol were excreted primarily as glucuronide conjugates. The remaining 
metabolites were observed as a mixture of both sulfate and glucuronide conjugates. The identities of the 
phase I metabolites were confirmed by comparison to synthetic reference materials where available, and 
the NIST spectral database, or tentatively assigned through a combination of their MS behaviour and 
relative elution order. Hydroxylation at C16 is a common pathway for steroid metabolism in the horse 39, 
and the authors rationalise the observed hydroxylated metabolite on this basis. The metabolites of Δ1-
androgens are also known to have similar mass spectra, which may complicate analysis 115. The identity of 
the phase II metabolites was further confirmed through the hydrolysis of the fractionated glucuronide and 
sulfate metabolites to their corresponding phase I metabolites and their identities assigned as stated 
above. A number of the observed metabolites were identified up to 72 hr post-administration, however the 
authors comment that these are also potential in vivo metabolites for endogenous steroid compounds such 
as testosterone 76. The metabolites containing the C1-C2 double bond are characteristic of administration 
of Δ1-testosterone, but were observed only 2-6 hr post-administration. The authors recommend 
monitoring for the parent compound, which can be detected at low levels (5-9 ng/mL) up to 30 hr post-
administration. Additionally, longer term detection may be possible by adopting thresholds for the 
endogenous metabolites, or using longitudinal monitoring of the steroid profile. 
 
As a part of this study, a comparative in vitro study was also undertaken. Phase I metabolism using equine 
liver microsomes prepared from whole liver tissue afforded six metabolites: three reduced metabolites (5α-
androst-1-ene-3α,17β-diol, 5α-androstane-3β,17β-diol, and epiandrosterone), two hydroxylated 
metabolites, and one oxidised metabolite (5α-androst-1-ene-3,17-dione). The majority of the observed in 
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vitro metabolites appear to correlate with the phase I metabolites observed after hydrolysis of the phase II 
metabolites observed in vivo.  
Tetrahydrogestrinone (18β-homo-17β-hydroxy-19-nor-17α-pregna-4,9,11-
trien-3-one) and structural analogues 
Figure 14 
 
Tetrahydrogestrinone (THG) was the second “designer” steroid ever reported and was identified during the 
analysis of a spent syringe containing an allegedly undetectable anabolic steroid which was provided 
anonymously to USADA in 2004 27–29. It can be produced chemically via a one-step reduction of gestrinone, 
which is a legally available progestin, and was originally produced with the express intention of bypassing 
current screening protocols 27. Since its initial discovery, it has been reported in several studies to exert 
strong activity in yeast 28,63,116,117 and mammalian AR CALUX 61 androgen bioassays. After its discovery, it 
was specifically banned in competition by WADA rather than relying on the phrasing “…and other 
substances with a similar chemical structure or biological effect(s).” 118 as it represented a whole new class 
of threat to anti-doping analysis.  
 
Following an equine in vivo controlled oral administration (25 µg/kg, 10 geldings) 119, THG has been 
reported to be excreted unmetabolised. An excretion profile was established for both plasma and urinary 
excretion. In plasma, concentrations peaked between 1-2 hr post-administration and were below the limit 
of detection at 24 hr post-administration. In urine, concentrations peaked at 3-6 hr post-administration and 
were below the limit of detection 48 hr post-administration.  
 
In a separate in vitro study using equine liver microsomes and S9 fraction 44, it has been reported that 
metabolism of THG favours formation of hydroxylated metabolites. In this study, two major hydroxylated 
metabolites were observed, alongside one oxidised and hydroxylated metabolite. Additional minor 
metabolites were observed including a reduced metabolite, a reduced and hydroxylated metabolite, a 
dihydroxylated and direduced metabolite, a dihydroxylated and oxidised metabolite, two dihydroxylated 
and reduced metabolites, and two dihydroxylated and direduced metabolites. The sites of hydroxylation, 
oxidation, and reduction were not identified in this study. There appears to be little difference in the 
metabolites observed from incubation with equine liver microsomes or S9 fraction. The minor metabolites 
have relative ion abundances up to three orders of magnitude less than the primary metabolites. GC-MS 
analysis was complicated by the presence of numerous artefactual products resulting from enol-TMS ether 
derivatisation. Alternate derivatisation conditions for the formation of the enol-TMS derivatives, or the use 
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of alternate derivatives such as TMS ether or methyloxime-TMS ether (MOX-TMS) may alleviate some of 
the problems associated with derivatising conjugated enone systems 67. Alternatively, the authors 
recommend LC-MS as being most suitable for the detection of THG and many of its metabolites. 
 
In another in vitro metabolism study using equine liver microsomes and S9 fraction 48, the phase I 
metabolism and phase II glucuronylation of THG was reported. Following phase II metabolism, two 
hydroxylated metabolites were observed, alongside THG glucuronide, and two hydroxylated glucuronide 
metabolites. Metabolites were identified by analysis of the LC-MS/MS spectra. Glucuronylation of the 
tertiary alcohol was observed only at low levels, presumably reflecting the sterically hindered nature of this 
position. The positions of hydroxylation or glucuronylation were not identified in this study. Additionally, 
the in vitro metabolism of several related steroid 4,9,11-trienes were reported in this study. The 
metabolism of gestrinone (18β-homo-17β-hydroxy-19-nor-17α-pregna-4,9,11-trien-20-yn-3-one), 
trenbolone (17β-hydroxyestra-4,9,11-trien-3-one), and altrenogest (17β-hydroxy-17α-(prop-2-enyl)estra-
4,9,11-trien-3-one, allyltrenbolone) was reported but have been covered in previous reviews and are 
subject to routine screening in equine anti-doping laboratories 39,50,120,121. The equine metabolism of 
dihydrogestrinone (18β-homo-17β-hydroxy-19-nor-17α-pregna-4,9,11,20-tetraen-3-one) has not been 
previously reviewed and following in vitro metabolism, a reduced and hydroxylated metabolite was 
observed alongside dihydrogestrinone glucuronide. Although reduction could occur at a number of 
positions, it presumably occurs at the terminal alkene to afford hydroxylated THG, as the extended 
conjugation in the A-C rings typically resists metabolism 39. This compound is likely to be encountered as an 
impurity in preparations containing THG resulting from the incomplete the hydrogenation of gestrinone 27. 
The equine metabolism of propyltrenbolone (17β-hydroxy-17α-propylestra-4,9,11-trien-3-one) has also not 
been previously reviewed and following in vitro metabolism, three hydroxylated metabolites were 
observed alongside propyltrenbolone glucuronide, and three hydroxylated glucuronide metabolites.  
 
Trestolone (17β-hydroxy-7α-methylestr-4-en-3-one) 
Figure 15 
 
Trestolone is a C7-methylated analogue of nandrolone, which itself is a C19-norsteroid analogue of 
testosterone. Owing to the lack of the C19-methyl substituent, this compound is more resistant to 
metabolism by aromatase enzymes 122, increasing its potential half-life in the body. Dietary supplements 
labelled to contain trestolone such as TR3ST (Olympus Labs) and 7-MENT Alpha (Wyked Labs) have become 
available in recent years. It has been shown in bioassays with HeLa cells transfected with the human 
androgen receptor 123, human AR CALUX bioassays 124,125 and in vivo rat models 125–127 to be a potent 
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androgen, as well as exhibit strong binding to the human progesterone receptor 123. Trestolone has also 
been recently explored for use as a human male contraceptive as it has been shown to inhibit 
spermatogenesis without inducing androgen deficiency 126,128. It has also been shown to inhibit equine and 
human steroid aromatase enzymes 49.  
 
As a part of a study of human and equine steroid aromatase enzymes, the equine metabolism of trestolone 
has been studied by in vitro methods 49. Although an appropriate choice for the study of the steroid 
aromatase pathway, the placental microsomes employed in this study are unlikely to reflect the 
metabolism afforded by liver enzymes. Following incubation of tritium labelled trestolone with equine 
placental microsomes, four metabolites were detected. Two of the detected metabolites were determined 
to be estrogenic as they were extracted in a phenolic extraction assay. Additionally, they matched TLC 
retention factors and GC-MS fragmentation with reference standards for 7α-methylestradiol, and 7α-
methylestrone. The identities of the two remaining metabolites were not determined, although they were 
hypothesised to be intermediate compounds in androgen aromatisation, such as 1-hydroxytrestolone. 
These metabolites were not identified in control experiments utilising 4-hydroxyandrostenedione, a known 
aromatase enzyme inhibitor 49. Additional kinetic experiments also showed that trestolone competitively 
inhibited the aromatisation of androstenedione and testosterone, suggesting that it may also function as an 
aromatase inhibitor. As a part of this study, incubations were also performed using a purified equine 
testicular P450 aromatase enzyme. After metabolism, these experiments also showed the presence of 7α-
methylestradiol, as well as the two intermediates identified above, which were matched to the previous 
experiment. The authors recommend monitoring for the parent compound, alongside 7α-methylestradiol, 
and 7α-methylestrone for the detection of trestolone misuse. Additionally, alteration of the endogenous 
steroid profile due to aromatase inhibition could likely be detected through a threshold approach, or 
longitudinal monitoring of the equine steroid profile. 
 
Future Directions 
As laboratories respond to new threats, the directions of equine anti-doping research will shift, and will 
vary into the future. The importance of alternate testing matrices is gaining attention, with many 
jurisdictions incorporating these samples into routine testing. Hair has been reported to be a potentially 
long-term marker of steroid misuse 37,39 and these samples are easily acquired and processed in the 
laboratory. However, the use of hair as a matrix for drug detection could be problematic in jurisdictions 
that do not enforce out-of-competition drug use as the long excretion profiles of steroid compounds in hair 
could cast uncertainty as to whether a steroid was administered in- or out-of-competition. Blood is also 
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becoming a more common sample matrix, and it has been suggested that the levels of drug compounds in 
the bloodstream may indicate the potential for pharmacological effects in vivo 39. Blood excretion profiles 
have been shown to be short, especially when compared to urinary excretion 47,119, which may limit its 
suitability to anti-doping laboratories. However, since the administered drugs can often be directly 
detected unmetabolised in blood 129 or hair 37, the ability to detect drug precursors of endogenous steroids 
arises and the need to conduct equine metabolism studies is reduced. Urine is still likely to remain a 
valuable analytical matrix as it is routinely used in the majority of currently available methods, and many of 
the important analytical thresholds for endogenous substances have only been determined in urine. The 
use of both GC-MS and LC-MS technologies is likely to be vital for adequate coverage of AAS metabolites in 
anti-doping screening as these techniques each provide advantages for certain target analytes. 
 
The rapid increase in the prevalence of designer anabolic steroids present in “dietary” and “nutritional” 
supplements available online containing untested and unapproved anabolic agents, or the more recent 
emergence of selective androgen receptor modulators (SARMs) 58,130,131, is likely to pose a significant threat 
to the integrity of the industry if left unchecked. Both drug classes present a number of problems for anti-
doping laboratories resulting from their widely variable structures that will need to be addressed in the 
future. Due to ethical concerns over the potential detrimental effects to the health and welfare of animal 
subjects, in vitro techniques are rapidly gaining attention as tools to study the metabolism of these 
compounds. These techniques, as highlighted by multiple examples throughout this review, are rapidly 
improving, and can more faithfully generate a metabolic profile representative of in vivo systems which will 
greatly assist anti-doping analysis 45–47,51,114. Currently, AORC criteria allow for the use of in vitro-derived 
materials as standards for confirmatory analysis 35, and improvements to in vitro techniques may allow for 
the direct detection and confirmation of in vivo phase II metabolites by LC-MS/MS methods 39. 
 
Recent improvements in untargeted and open screening methods show that these methods are also 
gaining popularity. These methods screen for characteristic fragments, or fragmentation modes of 
metabolite families rather than targeting individual drug metabolites, and they have been demonstrated to 
be suitable for the detection of unknown compounds in analytical samples 70–73. The recent advancements 
made in affordable LC-HRAM and MSn technologies also have greatly assisted the translation of these 
methods into routine screening as they allow for the acquisition of high-quality data which may be 
retrospectively analysed once new compounds are identified or new methods are developed. The 
development of more powerful computational packages provided by manufacturers also has the potential 
to make metabolomics approaches practical enough to be undertaken routinely in laboratories.  
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The final promising advancement is the development of the Equine Biological Passport 74, which mirrors the 
Athlete Biological Passport maintained by WADA for human athletes 75. This approach would build a 
baseline profile from the routine sample analysis of all samples from an individual competing horse. Any 
future instances of doping would then be detected by abnormal changes between the baseline and a 
subsequent sample. Although there are a number of technical and administrative hurdles to overcome 
before this can be realised, this approach has the potential to effectively combat the misuse of anabolic 
steroids, and other doping agents in equine sports now and into the future. 
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Figures and Tables 
Table 1: Summary of the equine metabolism of designer steroids 
Steroid Phase I and Phase II metabolites Comments 
11-Adrenosterone 
(Ref 
44
) 
Predominately C3/C11/C17 mono/di/trireduced. 
Minor hydroxylated metabolites. 
Phase II metabolism not studied. 
Recommended analyte(s): 
Reduced 11-adrenosterone, 
11β-hydroxyandrosterone 
threshold of greater than 10 
µg/mL, or a 11β-
hydroxyandrosterone:11β-
hydroxyetiocholanolone ratio 
of greater than 20:1 have 
been suggested based on 
human studies. 
 
In vitro metabolism only. 
11-Adrenosterone and its 
metabolites are potentially 
endogenous, may require 
threshold for detection. 
ATD 
(Ref 
44,51
) 
Predominately C17-reduced. 
Minor C16-hydroxylated and mono/direduced 
metabolites. 
C17β-sulfate and C17α-glucuronide metabolites. 
Mixture of both sulfate and glucuronide minor 
metabolites. 
Recommended analyte(s): 
17β-hydroxyandrosta-1,4,6-
trien-3-one, and 17β-
hydroxyandrosta-4,6-dien-3-
one. 
 
Elevated testosterone 
observed in vivo, suggesting 
aromatase inhibition. 
Boldenone observed as an in 
vivo metabolite. 
3α-Chloro-17α-methyl-
5α-androstan-17β-ol 
(Ref 
29
) 
3α-Chloro-17α-methyl-5α-androstan-16α,17β-diol 
identified as the sole equine metabolite. 
Phase II metabolism not studied. 
Recommended analyte(s): 
3α-Chloro-17α-methyl-5α-
androstane-16α,17β-diol, and 
17α-methyl-5α-androstane-
3α,17β-diol. 
 
In vitro metabolism only. 
Potential elimination of C3-
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chloride to form madol. 
Desoxyvinyltestosterone 
(Ref 
39,79
) 
 
A number of A-ring enones were identified alongside 
minor A-ring hydroxylated, and A-ring reduced and 
dihydroxylated metabolites. Also identified metabolites 
resulting from reduction and hydroxylation of the vinyl 
group. 
Predominately glucuronide conjugated 
 
Recommended analyte(s): 
5α,17α-pregn-20-ene-
2α/β,3α/β,17β-triol, and 
5α,17α-pregn-1-ene-
3α/β,17β,20α/β,21-tetraol. 
 
A number of analogues were 
also studied in vitro. 
estra-4,9-diene-3,17-
dione 
(Ref 
39,80
) 
Major C17-reduced. 
Phase II metabolism not studied. 
Recommended analyte(s): 
17α/β-hydroxyestra-4,9-dien-
3-one  
 
In vitro metabolism only. 
Halodrol 
(Ref 
44
) 
Turinabol observed as the major metabolite. 
Minor C3-oxidised and hydroxylated metabolites. 
Phase II metabolism not studied. 
Recommended analyte(s): 
Turinabol (4-chloro-17β-
hydroxy-17α-methylandrosta-
1,4-diene-3-one). 
 
In vitro metabolism only. 
20-Hydroxyecdysone 
(Ref 
44
) 
No phase I metabolism observed. 
Phase II metabolism not studied. 
Recommended analyte(s): 
20-Hydroxyecdysone. 
 
In vitro metabolism only. 
Phase II metabolism likely to 
predominate in vivo. 
Formestane 
(Ref 
44,45
) 
Predominately C17-reduced, with minor C3/C17 
direduction. Predominately glucuronide conjugated. 
Recommended analyte(s): 
Formestane, and 4,17β-
dihydroxyandrost-4-en-3-one. 
 
No aromatase inhibition 
observed in vivo. 
Furazadrol 
(Ref 
46
) 
Major in vivo metabolites: furazadrol sulfate and 
furazadrol glucuronide. Minor hydroxylated and, 
oxidised and hydroxylated metabolites also observed. 
Predominately sulfate conjugated. 
Recommended analyte(s): 
Furazadrol, furazadrol 17-
sulfate, and furazadrol 17-
glucuronide. 
Methasterone 
(Ref 
44
) 
Predominately C3-reduced. 
Minor hydroxylated metabolites. 
Phase II metabolism not studied. 
Recommended analyte(s): 
2α,17α-dimethyl-5α-
androstane-3α/β,17β-diol. 
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In vitro metabolism only. 
Oxyguno 
(Ref 
47
) 
Predominately C3/C11 mono/direduced. 
Minor C20-hydroxylation and C17-epimerisation. 
C3 sulfate and glucuronide. C11 glucuronide only. 
Proposed C17-epi-oxyguno sulfate. 
Recommended analyte(s): 
Oxyguno, and 4-chloro-3,17β-
dihydroxy-17α-methyl-5α-
androstan-11-one. 
 
In vitro metabolism appears 
limited in its ability to predict 
in vivo metabolism. 
Δ1-Testosterone 
(Ref 
114
) 
Range of mono/direduced metabolites. 
Minor hydroxylated and reduced metabolites. 
Mixture of sulfate and glucuronide conjugates. 
Recommended analyte(s): 
Δ1-Testosterone. 
 
Some metabolites are 
potentially endogenous. 
Tetrahydrogestrinone 
(Ref 
44,48,119
) 
Excreted unmetabolised in vivo. 
Primarily hydroxylated in vitro. 
Hydroxylated glucuronide metabolites observed in 
vitro. 
Recommended analyte(s): 
Tetrahydrogestrinone. 
 
Related steroid 4,9,11-trienes 
also studied in vitro 
48
. 
Trestolone 
(Ref 
49
) 
7α-methylestradiol, 7α-methylestrone, and two 
unidentified metabolites. 
Phase II metabolism not studied. 
Recommended analyte(s): 
Trestolone, 
7α-methylestradiol, and 7α-
methylestrone. 
 
In vitro metabolism only. 
Aromatase inhibitor. 
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Figure 1: 17α-methyltestosterone showing steroid ring structure and IUPAC-
recommended atom and ring labelling 
 
Figure 2: Representative examples of the major steroid classes 
 
Figure 3: Structures of the first “designer” steroids: norbolethone, 
tetrahydrogestrinone, and madol 
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Figure 4 
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Figure 9 
 
Figure 10 
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Figure 14 
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